- Previous Close
269,000.00 - Open
266,500.00 - Bid 264,500.00 x --
- Ask 263,500.00 x --
- Day's Range
261,000.00 - 269,000.00 - 52 Week Range
243,500.00 - 377,000.00 - Volume
35,431 - Avg. Volume
84,830 - Market Cap (intraday)
3.379T - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jan 31, 2025 - Feb 4, 2025
- Forward Dividend & Yield 750.00 (0.27%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
399,802.78
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
www.hanmipharm.com2,270
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 128940.KS
View MorePerformance Overview: 128940.KS
Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 128940.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 128940.KS
View MoreValuation Measures
Market Cap
3.38T
Enterprise Value
3.68T
Trailing P/E
20.76
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.13
Price/Book (mrq)
3.13
Enterprise Value/Revenue
2.35
Enterprise Value/EBITDA
10.54
Financial Highlights
Profitability and Income Statement
Profit Margin
11.75%
Return on Assets (ttm)
8.67%
Return on Equity (ttm)
18.22%
Revenue (ttm)
1.57T
Net Income Avi to Common (ttm)
184.38B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
246.89B
Total Debt/Equity (mrq)
42.55%
Levered Free Cash Flow (ttm)
158.89B